search
Back to results

CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease (SPIN)

Primary Purpose

Crohn Disease, Insomnia, Sleep Disturbance

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive Behavioral Therapy for Insomnia
Sponsored by
Dartmouth-Hitchcock Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Crohn Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild to moderate Crohn's disease (as assessed by PRO-3 score)
  • Insomnia severity index score of 8 or greater
  • Sleep onset latency and/or wake after sleep onset of at least 30 minutes
  • Access to device and internet/cell phone service sufficient for telehealth

Exclusion Criteria:

  • PHQ-9 score of 20 or greater
  • GAD-7 score of 20 or greater
  • Unstable major psychiatric condition
  • Current alcohol or substance abuse
  • Current narcotic use for pain control
  • Current systemic corticosteroid use
  • Current pregnancy or nursing
  • Ileostomy or colostomy
  • Diagnosis of seizure disorder
  • Diagnosis of sleep apnea or positive STOP-Bang screen
  • Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RLSq screen
  • Night shift, rotating shift work, or frequent travel outside of primary time zone

Sites / Locations

  • Dartmouth-Hitchcock Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Cognitive Behavioral Therapy for Insomnia

Waitlist

Arm Description

CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. Five CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.

No intervention for 8 weeks.

Outcomes

Primary Outcome Measures

Change in insomnia symptoms as measured by the Insomnia Severity Index
The Insomnia Severity Index (ISI) is a self-report questionnaire designed to measure severity of insomnia. The ISI is made up of 7 items on insomnia symptoms and related impairments and total scores range from 0-28. Higher scores are indicative of greater insomnia symptoms.
Change in diary-based sleep onset latency
A weekly average of self-reported time it takes to fall asleep each night, derived from a self-reported sleep diary
Change in diary-based wake after sleep onset
A weekly average of self-reported time spent awake in the middle of each night, derived from a self-reported sleep diary

Secondary Outcome Measures

Change in sleep efficiency based on diary
Change in sleep efficiency (total sleep time / time in bed), derived from a self-reported sleep diary
Change in sleep efficiency based on actigraphy
Change in sleep efficiency (total sleep time / time in bed) as measured by actigraphy (actigraph)
Change in diary sleep efficiency based on ambulatory EEG monitoring
Change in sleep efficiency (total sleep time / time in bed) as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Change in sleep onset latency as measured by actigraphy
Change in sleep onset latency as measured by actigraphy (actigraph)
Change in wake after sleep onset as measured by actigraphy
Change in wake after sleep onset as measured by actigraphy (actigraph)
Change in sleep onset latency as measured by ambulatory EEG monitoring
Change in sleep onset latency as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Change in wake after sleep onset as measured by ambulatory EEG monitoring
Change in wake after sleep onset as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Change in self-reported pain as measured by the Brief Pain Inventory
The Brief Pain Inventory will be used to assess pain location, severity, and interference. Pain severity is rated from 0-10 and pain interference is rated from 0-10; higher scores indicate more severe pain and more pain interference.
Change in behaviorally assessed pain tolerance via the Cold Pressor Test
The Cold Pressor Test involves submerging one's non-dominant hand in ice water and rating discomfort at regular, pre-determined intervals. Pain tolerance will be measured based on the total amount of time a participant can keep their hand submerged, with a maximum of 2 minutes.
Change in self-reported Crohn's disease symptoms as measured by the Patient Reported Outcomes-3
The Patient Reported Outcomes-3 is a self-report questionnaire that assesses frequency of diarrhea, severity of abdominal pain, and overall well-being. Higher scores indicate more severe Crohn's disease symptoms.
Change in time spent in slow wave sleep
We will measure percentage of time spent in slow wave sleep during a night's sleep using the Sleep Profiler, an ambulatory EEG sleep monitor
Change in C-reactive protein
We will measure blood levels of C-reactive protein
Change in fecal calprotectin
We will measure levels of fecal calprotectin via a stool sample.

Full Information

First Posted
September 1, 2021
Last Updated
May 17, 2023
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Crohn's and Colitis Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05034159
Brief Title
CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease
Acronym
SPIN
Official Title
A Pilot Trial of CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
October 22, 2021 (Actual)
Primary Completion Date
April 19, 2023 (Actual)
Study Completion Date
April 19, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Crohn's and Colitis Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
People with Crohn's disease often suffer from sleep problems. Long term, sleep problems may lead to more flares of Crohn's disease or other complications. In general, people with Crohn's disease also report that sleep problems can worsen symptoms of Crohn's disease the next day. In people with other medical problems, research has also shown that having sleep problems can make other things worse, such as pain and inflammation. In this study, the researchers want to understand the treatment of sleep problems in people with Crohn's disease, and what else might improve if sleep gets better. This study will use Cognitive Behavioral Therapy for Insomnia (CBT-I) to treat insomnia symptoms. CBT-I is the recommended treatment for insomnia and has been shown to improve sleep problems, pain, and inflammation in other groups of people. If this study is successful, it will contribute to understanding how to treat insomnia in people with Crohn's disease and how sleep impacts pain and inflammation. Long term, this information will be helpful in understanding how best to take care of people with Crohn's disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease, Insomnia, Sleep Disturbance, Pain, Inflammation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Following a baseline assessment, participants are initially randomized to either CBT-I or waitlist. Those in the waitlist condition will repeat their baseline assessment after 8 weeks, then will start CBT-I.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Behavioral Therapy for Insomnia
Arm Type
Experimental
Arm Description
CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. Five CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Arm Title
Waitlist
Arm Type
No Intervention
Arm Description
No intervention for 8 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy for Insomnia
Intervention Description
Same as is described previously.
Primary Outcome Measure Information:
Title
Change in insomnia symptoms as measured by the Insomnia Severity Index
Description
The Insomnia Severity Index (ISI) is a self-report questionnaire designed to measure severity of insomnia. The ISI is made up of 7 items on insomnia symptoms and related impairments and total scores range from 0-28. Higher scores are indicative of greater insomnia symptoms.
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in diary-based sleep onset latency
Description
A weekly average of self-reported time it takes to fall asleep each night, derived from a self-reported sleep diary
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in diary-based wake after sleep onset
Description
A weekly average of self-reported time spent awake in the middle of each night, derived from a self-reported sleep diary
Time Frame
From baseline assessment to 1-month post intervention
Secondary Outcome Measure Information:
Title
Change in sleep efficiency based on diary
Description
Change in sleep efficiency (total sleep time / time in bed), derived from a self-reported sleep diary
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in sleep efficiency based on actigraphy
Description
Change in sleep efficiency (total sleep time / time in bed) as measured by actigraphy (actigraph)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in diary sleep efficiency based on ambulatory EEG monitoring
Description
Change in sleep efficiency (total sleep time / time in bed) as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in sleep onset latency as measured by actigraphy
Description
Change in sleep onset latency as measured by actigraphy (actigraph)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in wake after sleep onset as measured by actigraphy
Description
Change in wake after sleep onset as measured by actigraphy (actigraph)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in sleep onset latency as measured by ambulatory EEG monitoring
Description
Change in sleep onset latency as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in wake after sleep onset as measured by ambulatory EEG monitoring
Description
Change in wake after sleep onset as measured by ambulatory EEG sleep architecture monitoring (sleep profiler)
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in self-reported pain as measured by the Brief Pain Inventory
Description
The Brief Pain Inventory will be used to assess pain location, severity, and interference. Pain severity is rated from 0-10 and pain interference is rated from 0-10; higher scores indicate more severe pain and more pain interference.
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in behaviorally assessed pain tolerance via the Cold Pressor Test
Description
The Cold Pressor Test involves submerging one's non-dominant hand in ice water and rating discomfort at regular, pre-determined intervals. Pain tolerance will be measured based on the total amount of time a participant can keep their hand submerged, with a maximum of 2 minutes.
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in self-reported Crohn's disease symptoms as measured by the Patient Reported Outcomes-3
Description
The Patient Reported Outcomes-3 is a self-report questionnaire that assesses frequency of diarrhea, severity of abdominal pain, and overall well-being. Higher scores indicate more severe Crohn's disease symptoms.
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in time spent in slow wave sleep
Description
We will measure percentage of time spent in slow wave sleep during a night's sleep using the Sleep Profiler, an ambulatory EEG sleep monitor
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in C-reactive protein
Description
We will measure blood levels of C-reactive protein
Time Frame
From baseline assessment to 1-month post intervention
Title
Change in fecal calprotectin
Description
We will measure levels of fecal calprotectin via a stool sample.
Time Frame
From baseline assessment to 1-month post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mild to moderate Crohn's disease (as assessed by PRO-3 score) Insomnia severity index score of 8 or greater Sleep onset latency and/or wake after sleep onset of at least 30 minutes Access to device and internet/cell phone service sufficient for telehealth Exclusion Criteria: PHQ-9 score of 20 or greater GAD-7 score of 20 or greater Unstable major psychiatric condition Current alcohol or substance abuse Current narcotic use for pain control Current systemic corticosteroid use Current pregnancy or nursing Ileostomy or colostomy Diagnosis of seizure disorder Diagnosis of sleep apnea or positive STOP-Bang screen Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RLSq screen Night shift, rotating shift work, or frequent travel outside of primary time zone
Facility Information:
Facility Name
Dartmouth-Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease

We'll reach out to this number within 24 hrs